Advanced search
Publication Cover
Cancer Investigation Volume 23, 2005 - Issue 1
Submit an article Journal homepage
69
Views
31
CrossRef citations to date
0
Altmetric
Original Article

Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study

Nikolaos Androulakis Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece
,
Konstantinos Syrigos Medical Oncology Unit 3, Department of Internal Medicine, Hospital of Pulmonary Diseases, Athens, Greece
,
Aristidis Polyzos Medical Oncology Unit, “Laiko” Hospital of Athens, Athens, Greece
,
Gerasimos Aravantinos 3rd Department of Medical Oncology, Agii Anargyri Anticancer Hospital, Athens, Greece
,
George P. Stathopoulos Medical Oncology Unit, “E. Dynan” General Hospital, Athens, Greece
,
Nikolaos Ziras Department of Medical Oncology, “METAXA” Anticancer Hospital, Athens, Greece
,
Konstantinos Mallas Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece
,
Lambros Vamvakas Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece
,
Vassilis Georgoulias Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece; Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece
, Ph.D. , M.D. &
for the Hellenic Oncology Research Group (HORG) Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece; Medical Oncology Unit 3, Department of Internal Medicine, Hospital of Pulmonary Diseases, Athens, Greece; Medical Oncology Unit, “Laiko” Hospital of Athens, Athens, Greece; 3rd Department of Medical Oncology, Agii Anargyri Anticancer Hospital, Athens, Greece; Medical Oncology Unit, “E. Dynan” General Hospital, Athens, Greece; Department of Medical Oncology, “METAXA” Anticancer Hospital, Athens, Greece
 show all
Pages 9-12 | Published online: 11 Jun 2009

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Jie Hua, Si Shi, Dingkong Liang, Chen Liang, Qingcai Meng, Bo Zhang, Quanxing Ni, Jin Xu & Xianjun Yu. (2018) Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. OncoTargets and Therapy 11, pages 4591-4608.
Read now
Mohammad Aminzadeh, Hassan Mansouri-Torshizi & Ali Reza Modarresi-Alam. (2017) 2,2′- bipyridine coplanar with coordination square of Pd(II) nonyldithiocarbamato antitumor complex interacting with DNA in two distinct steps. Journal of Biomolecular Structure and Dynamics 35:11, pages 2301-2313.
Read now
Sana Saif Ur Rehman, Kian Lim & Andrea Wang-Gillam. (2016) Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Expert Review of Anticancer Therapy 16:5, pages 485-492.
Read now
Concetta Elisa Onesti, Adriana Romiti, Michela Roberto, Rosa Falcone & Paolo Marchetti. (2015) Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Review of Anticancer Therapy 15:10, pages 1183-1198.
Read now

Articles from other publishers (27)

Satoshi Kobayashi, Shun Tezuka, Yui Yamachika, Shotaro Tsunoda, Shuhei Nagashima, Yuichiro Tozuka, Taito Fukushima, Manabu Morimoto, Makoto Ueno, Junji Furuse & Shin Maeda. (2023) FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study. BMC Cancer 23:1.
Crossref
Yuchao Zhang, Gang Xu, Maozhen Chen, Qian Wei, Tengteng Zhou, Ziliang Chen, Mingyang Shen & Ping Wang. (2020) Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. Frontiers in Oncology 10.
Crossref
Giuseppe Aprile, Francesca V. Negri, Francesco Giuliani, Elisa De Carlo, Davide Melisi, Francesca Simionato, Nicola Silvestris, Oronzo Brunetti, Francesco Leone, Donatella Marino, Daniele Santini, Emanuela Dell’Aquila, Tea Zeppola, Marco Puzzoni & Mario Scartozzi. (2017) Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology 115, pages 1-12.
Crossref
Adnan M. Nagrial, Venessa T. Chin, Katrin M. Sjoquist, Marina Pajic, Lisa G. Horvath, Andrew V. Biankin & Desmond Yip. (2015) Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology/Hematology 96:3, pages 483-497.
Crossref
Andrea Teague, Kian-Huat Lim & Andrea Wang-Gillam. (2015) Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Therapeutic Advances in Medical Oncology 7:2, pages 68-84.
Crossref
Xu Li, Feng Zhu, Jianxin Jiang, Chengyi Sun, Xin Wang, Ming Shen, Rui Tian, Chengjian Shi, Meng Xu, Feng Peng, Xingjun Guo, Min Wang & Renyi Qin. (2015) Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells. Cancer Letters 357:1, pages 219-230.
Crossref
Aziz Zaanan, Isabelle Trouilloud, Theofano Markoutsaki, Mélanie Gauthier, Anne-Claire Dupont-Gossart, Thierry Lecomte, Thomas Aparicio, Pascal Artru, Anne Thirot-Bidault, Fanny Joubert, Daniella Fanica & Julien Taieb. (2014) FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer 14:1.
Crossref
Helmut OettleHanno RiessJens M. StielerGerhard HeilIngo SchwanerJörg SeraphinMartin GörnerMatthias MölleTim F. GretenVolker LaknerSven BischoffMarianne SinnBernd DörkenUwe Pelzer. (2014) Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. Journal of Clinical Oncology 32:23, pages 2423-2429.
Crossref
Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski & Sheldon Brookman. (2014) Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer—A Potential Strategy for Improved Survival. Journal of Cancer Therapy 05:12, pages 1072-1091.
Crossref
Hend Ahmed El-Hadaad & Hanan Ahmed Wahba. (2013) Oxaliplatin Plus 5-Fluorouracil and Folinic Acid (OFF) in Gemcitabine-Pretreated Advanced Pancreatic Cancer: A Phase II Study. Journal of Gastrointestinal Cancer 44:3, pages 313-317.
Crossref
O.E. Rahma, A. Duffy, D.J. Liewehr, S.M. Steinberg & T.F. Greten. (2013) Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Annals of Oncology 24:8, pages 1972-1979.
Crossref
SEUNG BAE RHO, HYUN-JUNG BYUN, BOH-RAM KIM, IK SUN KIM, JEONG HEON LEE, RICHARD YOO, SUNG TAEK PARK & SUNG HO PARK. (2013) GABAA receptor-binding protein promotes sensitivity to apoptosis induced by chemotherapeutic agents. International Journal of Oncology 42:5, pages 1807-1814.
Crossref
HYUN JUNG KIM, JINA YUN, HAN JO KIM, KYOUNG HA KIM, SE HYUNG KIM, TAE HOON LEE, SANG-CHEOL LEE, SANG BYUNG BAE, CHAN KYU KIM, NAM SU LEE, JONG HO MOON, SANG HEUM PARK, KYU TAEK LEE, SEONG KYU PARK, JONG-HO WON, HEE SOOK PARK & DAE SIK HONG. (2012) Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients. Oncology Letters 3:6, pages 1314-1318.
Crossref
György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella, Tudor Eliade Ciuleanu, G. Pover & N. C. Tebbutt. (2011) A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Investigational New Drugs 30:3, pages 1216-1223.
Crossref
Sung Ho Park, Jeong Heon Lee, Gwang-Beom Lee, Hyun-Jung Byun, Boh-Ram Kim, Chan-Yong Park, Hong-Bae Kim & Seung Bae Rho. (2012) PDCD6 additively cooperates with anti-cancer drugs through activation of NF-κB pathways. Cellular Signalling 24:3, pages 726-733.
Crossref
José Eduardo M. Cunha, Marcos V. Perini & Daniela Freitas. 2012. Cancer Metastasis. Cancer Metastasis 333 343 .
Sanjeev Banerjee, Dejuan Kong, Asfar S. Azmi, Zhiwei Wang, Aamir Ahmad, Seema Sethi & Fazlul H. Sarkar. (2010) Retracted: Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine‐resistant pancreatic cancer cells in vitro and in vivo . International Journal of Cancer 128:5, pages 1240-1250.
Crossref
John P. Neoptolemos, Raul Urrutia, James L. Abbruzzese & Markus W. BüchlerAlicia Okines, Gihan Ratnayake, Ian Chau & David Cunningham. 2010. Pancreatic Cancer. Pancreatic Cancer 913 949 .
Ana Custodio, Javier Puente, Javier Sastre & Eduardo Díaz-Rubio. (2009) Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions. Cancer Treatment Reviews 35:8, pages 676-684.
Crossref
Daniela Freitas, Gustavo Dos Santos Femandes, Paulo M. Hoff & Jose Eduardo Cunha. (2009) Medical Management of Pancreatic Adenocarcinoma. Pancreatology 9:3, pages 223-232.
Crossref
Chigusa Morizane, Takuji Okusaka, Junji Furuse, Hiroshi Ishii, Hideki Ueno, Masafumi Ikeda, Kohei Nakachi, Mina Najima, Takashi Ogura & Eiichiro Suzuki. (2008) A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology 63:2, pages 313-319.
Crossref
Henry Q. Xiong, Gauri R. Varadhachary, Joan C. Blais, Kenneth R. Hess, James L. Abbruzzese & Robert A. Wolff. (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer. Cancer 113:8, pages 2046-2052.
Crossref
Sameer P. Desai & Mark M. Zalupski. 2008. Pancreatic Cancer. Pancreatic Cancer 511 533 .
Kohei Nakachi, Junji Furuse, Hiroshi Ishii, Ei-ichiro Suzuki & Masahiro Yoshino. (2007) Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer. Japanese Journal of Clinical Oncology 37:2, pages 114-120.
Crossref
Jirong Bai, Aram Demirjian, Jianhua Sui, Wayne Marasco & Mark P. Callery. (2006) Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochemical and Biophysical Research Communications 348:4, pages 1245-1253.
Crossref
A Demols, M Peeters, M Polus, R Marechal, F Gay, E Monsaert, A Hendlisz & J L Van Laethem. (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. British Journal of Cancer 94:4, pages 481-485.
Crossref
Michail Ignatiadis, Aris Polyzos, George P. Stathopoulos, Evangelos Tselepatiotis, Charalambos Christophylakis, Kostas Kalbakis, Lambros Vamvakas, Athanasios Kotsakis, Anna Potamianou & Vassilis Georgoulias. (2006) A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer. Oncology 71:3-4, pages 159-163.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.